NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Sell
19
CYTOF Quote, Financials, Valuation and Earnings
Last price:
$0.10
Seasonality move
:
-17.35%
Day range:
$0.10 - $0.20
52-week range:
$0.10 - $3.60
Dividend yield:
0%
P/E ratio:
0.25x
P/S ratio:
--
P/B ratio:
0.07x
Volume:
745.1K
Avg. volume:
227.7K
1-year change:
-95.56%
Market cap:
$452.7K
Revenue:
$188.4K
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingAltamira Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Altamira Therapeutics has an estimated upside of 4364.98% from its current price of $0.12.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.12.
Fair Value
-
According to the consensus of 0 analysts, Altamira Therapeutics has 4364.98% upside to fair value with a price target of -- per share.
CYTOF vs. S&P 500
-
Over the past 5 trading days, Altamira Therapeutics has underperformed the S&P 500 by -71.84% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Altamira Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Altamira Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Altamira Therapeutics reported revenues of --.
Earnings Growth
-
Altamira Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Altamira Therapeutics reported earnings per share of --.
Enterprise value:
387.2K
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2017-12-31 | 2018-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -$5.6M | -$646.4K | |
| EBITDA | -- | -- | -- | -$4.3M | -$3.4M | |
| Diluted EPS | -- | -- | -- | -$8,212.79 | -$975.07 | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $409.8K | $9.9M | $2M | $1.9M | $524K | |
| Total Assets | $8.4M | $25.8M | $19.4M | $6.9M | $8.1M | |
| Current Liabilities | $2.5M | $3.3M | $10.3M | $6M | $1.2M | |
| Total Liabilities | $3.7M | $4M | $11.3M | $8.9M | $1.8M | |
| Total Equity | $4.7M | $21.8M | $8M | -$2M | $6.3M | |
| Total Debt | -- | -- | $4.9M | $3.4M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2017-12-31 | 2018-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$6.6M | -$1.9M | |
| Cash From Investing | -- | -- | -- | -$6.6K | -$1.9M | |
| Cash From Financing | -- | -- | -- | $1.1M | $4M | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
CYTOF
Sector
Market Cap
$452.7K
$43.9M
Price % of 52-Week High
3.33%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-95.56%
-29.11%
Beta (5-Year)
2.426
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.38
200-day SMA
Sell
Level
$1.09
Bollinger Bands (100)
Sell
Level
0.44 - 0.88
Chaikin Money Flow
Sell
Level
-722.6M
20-day SMA
Sell
Level
$0.42
Relative Strength Index (RSI14)
Sell
Level
16.63
ADX Line
Sell
Level
25.56
Williams %R
Buy
Level
-96.0743
50-day SMA
Sell
Level
$0.47
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
2B
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-20.7346)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens. The company's OligoPhore / SemaPhore platform is a versatile system that allows the complexation of therapeutic RNAs with a proprietary peptide to form a nanoparticle formulation. This formulation allows to deliver of therapeutic RNA by systemic administration to tissues affected by leaky vasculature, a hallmark of solid tumors and certain inflammatory conditions.
Stock Forecast FAQ
In the current month, CYTOF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CYTOF average analyst price target in the past 3 months is --.
-
Where Will Altamira Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Altamira Therapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Altamira Therapeutics?
Analysts are divided on their view about Altamira Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Altamira Therapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is Altamira Therapeutics's Price Target?
The price target for Altamira Therapeutics over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CYTOF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Altamira Therapeutics is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CYTOF?
You can purchase shares of Altamira Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Altamira Therapeutics shares.
-
What Is The Altamira Therapeutics Share Price Today?
Altamira Therapeutics was last trading at $0.10 per share. This represents the most recent stock quote for Altamira Therapeutics. Yesterday, Altamira Therapeutics closed at $0.12 per share.
-
How To Buy Altamira Therapeutics Stock Online?
In order to purchase Altamira Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 4.37% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 8.88% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.98% over the past day.
